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Original Study

Patient-Reported Outcomes Data From REVEAL
at the Time of Enrollment (Baseline): A
Prospective Observational Study of Patients With
Polycythemia Vera in the United States
Ruben Mesa,1 Ralph V. Boccia,2 Michael R. Grunwald,3 Stephen T. Oh,4
Philomena Colucci,5 Dilan Paranagama,5 Shreekant Parasuraman,5 Brady L. Stein6
Abstract
Data from REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices; n [ 2309), the ﬁrst study of its kind, conﬁrm that many patients experience quality of life and work
productivity impairments that might negatively affect their lives. In the future, longitudinal data from REVEAL
will be important for evaluating how such burdens change over time.
Background: Patients with polycythemia vera (PV) often experience symptoms that adversely affect their quality of life
(QoL). The ongoing, prospective, observational REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices) study was designed to collect contemporary data regarding burden of disease,
clinical management, patient-reported outcomes (PROs), and health care resource utilization from adult patients with
PV in the United States. Patients and Methods: Data on PROs were collected at enrollment using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS; range, 0-100); the European
Organization for Research and Treatment of CancereCore Quality of Life Questionnaire, version 3.0 (EORTC QLQC30; range, 0-100); and the Work Productivity and Activity Impairment QuestionnaireeSpeciﬁc Health Problem
(WPAI-SHP; range, 0%-100%). Results: Among 2309 patients, mean (SD) disease duration was 5.8 (6.1) years and
Charlson Comorbidity Index was 3.4 (0.8); 54.0% (1247/2309) were male. Mean (SD) MPN-SAF TSS was 18.8 (15.5).
The most common symptoms were fatigue (80.1% [1844/2302]), early satiety (60.9% [1402/2302]), and inactivity
(57.6% [1324/2302]). The most common severe symptoms were fatigue (16.8% [387/2302]), itching (13.4% [308/
2302]), and inactivity (11.8% [271/2302]). The mean (SD) EORTC QLQ-C30 global health status/QoL score was 73.1
(23.2): mean functional subscale scores ranged from 80.5 (23.9) for cognitive functioning to 85.7 (24.6) for social
functioning. The mean WPAI-SHP activity impairment score was 19.7% (n ¼ 2300). Employed patients had mean
WPAI-SHP scores for absenteeism, presenteeism, and overall work impairment of 3.2% (n ¼ 810), 12.1% (n ¼ 807),
and 13.4% (n ¼ 802), respectively. Conclusion: These data conﬁrm that many patients with PV experience symptoms,
QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL
will be important for evaluating how PROs change over time in these patients.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 9, 590-6 ª 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Activity impairment, Myeloproliferative neoplasm, Quality of life, Symptoms, Work productivity
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Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN)
primarily characterized by erythrocytosis and activating mutations in
the Janus kinase 2 gene.1 Patients with PV have an increased risk of
mortality compared with age- and sex-matched individuals in the
general population2 and experience a broad range of symptoms that
negatively affect their quality of life (QoL) and productivity.3-6 In the
recent MPN Landmark survey of US patients with MPNs, fatigue was
the most frequently reported symptom among patients with PV
(73%), and 49% of the patients described their fatigue as “very severe.”5 Many patients also reported itching (55%), night sweats
(45%), and concentration problems (36%). In addition to the various
symptoms associated with PV, approximately 40% of patients experience splenomegaly that resulted in occasional discomfort and pain.7
Findings from an international prospective study of 1334 patients with
PV (mean disease duration, 6.9 years)8 suggest that many patients
experience suboptimal symptom control with traditional treatments.
Most patients with PV in the MPN Landmark cross-sectional
survey reported feeling anxious or worried about their condition
(78%) and that their PV symptoms reduced their QoL (66%).5
Many patients also reported interference with family or social life
(63%), daily activities (48%), and normal work hours (37%). Most
of the observational studies of patients with PV have been reported
out of Europe3,6,9-11 or have been limited to single centers in the
United States.12,13 Administrative claims databases and electronic
medical records can be used to characterize patterns of care in
clinical practice; however, these data sources frequently lack patientreported outcomes (PROs) and can be limited in utility because of
selection bias and missing values. Cross-sectional surveys such as the
Landmark survey cannot characterize how PROs change over time.
With respect to the evolution of MPN-speciﬁc PROs, the
Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF) is a questionnaire that includes 17 MPN-related symptoms
and a single question pertaining to overall QoL that was designed to
assess the most impactful symptoms observed in patients with
MPNs.3,6 Subsequently, on the basis of the evaluation of the MPNSAF in clinical practice, it was concluded that an abbreviated version
was necessary.3 Consequently, the MPN-SAF Total Symptom Score
(TSS; also known as MPN10) was constructed and validated. This
shorter questionnaire includes a question pertaining to the worst
level of fatigue in the past 24 hours as well as the other 9 most
characteristic and clinically signiﬁcant MPN symptoms.3 Both
instruments remain in use. For example, in the National
Comprehensive Cancer Network’s clinical guidelines for MPNs, the
MPN-SAF and the MPN-SAF TSS are currently recommended for
the assessment of symptom burden at baseline and during the
course of treatment, respectively.14
The ongoing REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices;
ClinicalTrials.gov: NCT02252159) was designed to collect
contemporary data regarding the burden of disease, clinical management, PROs, and health care resource utilization of patients with
PV in the United States. The objective of the present report was to
characterize the PRO data from REVEAL at patient enrollment to
assess the symptom burden, QoL impairments, and work productivity impairments associated with PV.

Table 1 Demographic and Clinical Characteristics at
Enrollmenta
Characteristic
Mean (SD) Age, Years

All Patients (n [ 2309)
66.1 (12.1)

Age Group, Years, n (%)
18-34

28 (1.2)

35-59

618 (26.8)

60-74

1073 (46.5)

75

590 (25.6)

Sex, n (%)
Male

1247 (54.0)

Female

1062 (46.0)

Disease Duration, Years
Mean (SD)

5.8 (6.1)

Median (range)

4.1 (0-39.2)

Primary Employment Status
at PV Diagnosis, n (%)
Full-time

1121 (48.5)

Part-time

148 (6.4)

Retired

746 (32.3)

Homemaker

116 (5.0)

Unable to work/disabled

86 (3.7)

Other

46 (2.0)

Student

13 (0.6)

Unknown/missing

33 (1.4)

Employment Status at
Enrollment, n (%)
Full-time

669 (29.0)

Part-time
Retired

110 (4.8)
1176 (50.9)

Homemaker
Unable to work/disabled
Other

80 (3.5)
101 (4.4)
70 (3.0)

Student

6 (0.3)

Unknown/missing

97 (4.2)

PV Risk Status, n (%)
Low

528 (22.9)

Highb

1781 (77.1)

Mean (SD) Charlson Comorbidity
Index

3.4 (0.8)

Management of PV, n (%)
Watchful Waiting

123 (5.3)

Phlebotomy Only (With or
Without Aspirin)

787 (34.1)

Hydroxyurea (With or Without
Aspirin)

661 (28.6)

Hydroxyurea With Phlebotomy
(With or Without Aspirin)

550 (23.8)

Other

186 (8.1)

Missing

2 (0.1)

Abbreviation: PV ¼ polycythemia vera.
a
All patients with age and sex information enrolled on or before May 18, 2017, and with at least
1 nonmissing patient-reported outcome at enrollment.
b
High-risk PV deﬁned as patients with a history of thrombotic events and/or patients 60 years of
age or older.
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Figure 1 Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Symptom Severity at Enrollment.a Weight Loss
Indicates Unintentional Weight Loss in the Past 6 Months

Patients, % (n)

32.4 (746)

16.8 (387)

9.9
(229)

24.9 (573)

11.8
(271)

17.2 (397)

9.9
(229)

10.8
(248)

6.2
11.2
(142) (258)

8.4
(194)

10.9
(252)

42.5 (978)

22.5 (517)

24.0 (553)

15.8 (364)

9.3
(213)

39.1 (900)

26.1 (600)

23.3 (536)

13.4
(308)

23.7 (545)

46.8 (1077)

49.8 (1147)

19.9
(458)

20.5 (471)

17.8
(410)

10.0
4.1 6.6
(95) (151) (230)

19.9 (458)

30.9 (711)

59.4 (1367)

62.2 (1431)

62.8 (1446)

79.3 (1826)

0.6
(13)

7.2
(165)

91.1 (2098)

1.1
(26)

a

Each item was scored on a scale from 0 (absent) to 10 (worst imaginable). Only evaluable patients with MPN-SAF data (n ¼ 2302) were included.

Patients and Methods
Study Design
The REVEAL study is a multicenter, noninterventional, prospective, observational study of adult patients with PV. REVEAL is
being conducted in accordance with the Declaration of Helsinki;
institutional review board approval of all study materials is required,
and informed consent is required from all patients. Patients were
recruited over a 24-month enrollment period. All treatment decisions were made by the treating physician.
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Patients were eligible for inclusion if they were 18 years old or
older; had a clinical diagnosis of PV; were willing and able to
provide informed consent and complete patient assessments and
questionnaires, either alone or with minimal assistance from a
caregiver or trained site personnel; and were under physician supervision for the current management of their PV. Patients were
excluded if they were participating in an active, blinded clinical trial;
had a life expectancy <6 months; had a diagnosis of myeloﬁbrosis,
acute myeloid leukemia, or myelodysplastic syndrome; had a history

Ruben Mesa et al
Figure 2 Mean (SD) Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Symptom Scores at Enrollmenta

Mean (SD) MPN-SAF Symptom Severity Score

a
b

Each item was scored on a scale from 0 (absent) to 10 (worst imaginable). Only evaluable patients with MPN-SAF data (n ¼ 2302) were included.
Unintentional weight loss in the past 6 months.

of or active plan to proceed to allogeneic hematopoietic stem cell
transplantation within 3 months of enrollment; or had undergone
splenectomy.

Assessments
An objective of REVEAL was to collect PRO data pertaining to
health-related QoL, activity, and productivity impairment, and
symptom burden in patients with PV. PRO data were collected at
enrollment (baseline) and at 3-month intervals; the current analysis
was conducted on PRO data collected at enrollment.
Symptom burden was assessed with the MPN-SAF TSS (also
known as MPN10),3 which consists of 10 items (fatigue, early
satiety, abdominal discomfort, inactivity, problems with concentration, night sweats, itching, bone pain, fever, and unintentional
weight loss) graded from 0 (absent) to 10 (worst). Severity designations for the MPN-SAF TSS were: 0, absent; 1-3, mild; 4-6,
moderate; and 7, severe. The MPN-SAF TSS was deﬁned as the
sum of all 10 symptoms (range, 0-100). Health-related QoL was
assessed with the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire, version 3.0
(EORTC QLQ-C30),15 which is composed of 5 multi-item functional scales (physical, role, cognitive, emotional, and social), 3
multi-item symptom scales (fatigue, nausea/vomiting, and pain),
and a multi-item global health status/QoL scale. It also includes 6
single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and ﬁnancial difﬁculties) assessing additional symptoms.
Linear transformation to 0 to 100 was applied to raw scores (averages of the items contributing to the scale or individual item
values) to obtain scores for each scale or single item. Higher scores
for functional scales and global health status represent higher

functioning and better health status/QoL, respectively. However,
higher scores for symptom scales/items represent higher symptom
burden.
Work productivity and activity impairment were examined with the
Work Productivity and Activity Impairment QuestionnaireeSpeciﬁc
Health Problem (WPAI-SHP).16 Activity impairment was assessed for
all patients (7-day recall) as the percentage of impairment in daily
activities. The following work-related impairments were assessed
among employed patients only (7-day recall): absenteeism (percentage
of work time missed because of PV), presenteeism (percentage of
impairment while at work because of PV), and percentage overall work
impairment due to PV. For all WPAI-SHP items, higher percentages
indicate greater levels of impairment.
Morbidity was assessed using the Charlson Comorbidity Index
(CCI), which is not a PRO.17 The CCI rates International Classiﬁcation of Diseases diagnosis codes on a 6-point scale, with higher
scores indicating increasing severity (eg, increased risk of mortality
or resource use); the sum of these scores yields a single index value
for each patient (ie, there is no maximum value).

Statistics
All analyses were exploratory in nature and evaluated with
descriptive statistics. Statistical analysis of all data was performed
using SAS statistical software (SAS Institute Inc, Cary, NC) or other
commercially available standard statistical software.

Results
Demographic and Baseline Characteristics
Of the 2510 enrolled patients, 2309 had evaluable PRO data at
enrollment. These patients had a mean (SD) age of 66.1 (12.1)

Clinical Lymphoma, Myeloma & Leukemia September 2018

- 593

REVEAL Baseline PROs
Figure 3 Mean European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire (EORTC QLQ-C30)
Scores for (A) Symptom Subscales and (B) QoL and Functional Subscales at Enrollmenta

A

B

Mean (SD) Symptom Subscales

Mean (SD) QoL and Functional Subscales

Abbreviation: QoL, quality of life.
a
All scores were standardized using linear transformation to 0 to 100. Only evaluable patients with EORTC QLQ-C30 data (n ¼ 2298-2304 for each score) were included.

years, a median (range) disease duration of 4.1 (0-39.2) years, and a
mean (SD) CCI of 3.4 (0.8). At enrollment, most patients (94.6%
[2184/2309]) were managed with therapeutic interventions, the
most common being hydroxyurea with or without phlebotomy and
aspirin (52.4% [1211/2309]). A small proportion of patients were
under watchful waiting without any therapeutic interventions
(5.3% [123/2309]). More than half (55.0% [1269/2309]) of
enrolled patients reported being employed full- or part-time at the
time of their PV diagnosis, whereas approximately one-third (33.7%
[779/2309]) were employed at enrollment (Table 1).

Patient-Reported Outcomes
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Symptoms and Health-Related QoL. Of the 2307 patients with
MPN-SAF responses at enrollment, 93.3% (2152 of 2307) reported
at least 1 PV-related symptom. The most frequently reported
symptoms on the MPN-SAF TSS were fatigue (80.1%
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[1844/2302]), early satiety (60.9% [1402/2302]), and inactivity
(57.6% [1324/2302]; Figure 1). The most frequently reported severe symptoms (MPN-SAF TSS score 7) were fatigue (16.8%
[387/2302]), itching (13.4% [308/2302]), and inactivity (11.8%
[271/2302]; Figure 1). The mean (SD) MPN-SAF TSS total score
at enrollment was 18.8 (15.5). Symptoms with the highest reported
mean (SD) MPN-SAF TSS severity scores were fatigue (3.5 [2.7]),
early satiety (2.6 [2.7]), inactivity (2.5 [2.8]), itching (2.3 [3.0]),
and concentration problems (2.0 [2.6]; Figure 2).
The most severe mean (SD) symptom scores on the EORTC
QLQ-C30 at enrollment were fatigue (29.9 [27.8]), insomnia (28.8
[33.9]), pain (20.0 [28.2]), and dyspnea (17.2 [27.5]; Figure 3A).
The mean (SD) EORTC QLQ-C30 global health status/QoL score
at enrollment was 73.1 (23.2), with mean functional scores ranging
from 80.5 (23.9) for cognitive functioning to 85.7 (24.6) for social
functioning (Figure 3B).

Ruben Mesa et al
Figure 4 Mean Work Productivity and Activity Impairment QuestionnaireeSpeciﬁc Health Problem Scores at Enrollmenta

Abbreviation: PV ¼ polycythemia vera.
a
All items on the basis of 7-day recall (ie, regarding work/activity during the 7 days preceding the survey).

Work Productivity and Activity Impairment. Patients experienced
notable work productivity and activity impairments in the 7 days
preceding the assessment at enrollment (Figure 4). The mean activity impairment score at enrollment, regardless of employment
status, was 19.7% (n ¼ 2300). Among employed patients, mean
WPAI-SHP scores for absenteeism, presenteeism, and overall work
impairment at enrollment were 3.2% (n ¼ 810), 12.1% (n ¼ 807),
and 13.4% (n ¼ 802), respectively.

Discussion
The REVEAL study is the ﬁrst large, prospective, observational
study aimed at examining the contemporary demographic characteristics, burden of disease, clinical management, PROs, and health
care resource utilization in patients with PV in the United States.
Enrolled patients represent a broad, real-world segment of the PV
population that is actively undergoing treatment at community or
academic centers. REVEAL is unique in that it is a prospective,
longitudinal study of American patients in a variety of clinical practice
settings.
At the time of enrollment in the REVEAL study, most patients
noted the presence of symptoms. On the MPN-SAF TSS, fatigue,
early satiety, and inactivity were the most common and the most
severe symptoms reported. QoL parameters assessed with the
EORTC QLQ-C30 conﬁrmed disease burden in patients with the
most severe scores reported for fatigue, insomnia, and pain. Among
patients who were employed at the time of enrollment, absenteeism
and impairment while at work were attributed to their PV. However, in light of the median age at diagnosis (60.3 years), a decline in

the proportion of patients employed at the time of diagnosis (55.0%
[1269/2309]) compared with enrollment (33.7% [779/2309]) is
likely attributable to age and symptom burden.
In the ﬁrst publication in which the MPN-SAF TSS was used to
assess symptom burden in an international cohort of patients with
MPNs, there were MPN-SAF TSS data reported for 538 patients
with PV.3 The symptoms with the highest mean scores included
fatigue, pruritus, concentration problems, early satiety, and inactivity. In a subsequent study, the MPN-SAF TSS was used to
prospectively evaluate 1334 international patients with PV to
determine how previous hydroxyurea use, phlebotomy requirements, and palpable splenomegaly contributed alone or in
aggregate to PV symptom burden.8 Among all patients, the highest
mean scores included fatigue, concentration problems, pruritus,
inactivity, and early satiety. When evaluating results reported from
REVEAL as well as these 2 other prospective studies, fatigue was
consistently the symptom with the highest mean score. Similarly, in
all 3 of these prospective studies, the symptoms with the highest
mean scores (fatigue, early satiety, inactivity, pruritus, and concentration problems) were consistent, although the rank order of the
second through ﬁfth highest mean scores varied.
With respect to the EORTC QLQ-C30 score results, the mean
(SD) duration of PV in REVEAL patients was 5.8 (6.1) years and
the mean (SD) global health status/QoL score was 73.3 (23.2). In
other prospective studies6,11 in which mean global health/QoL
scores were reported for non-newly diagnosed patients (mean
duration of PV not reported) and for newly diagnosed patients, the
mean global health status/QoL scores were 65.7 and 69.7,
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respectively. Disease duration and study location might have
contributed to differences in the mean global health status/QoL
scores. However, there were consistencies among the 3 studies; for
example, in all 3 studies, the 4 EORTC QLQ-C30 symptoms with
the highest mean scores included fatigue, insomnia, dyspnea, and
pain.6,11
Data from the WPAI-SHP indicate that PV affects activities of
daily living in all patients, and for those who are working, the overall
work impairment in patients with PV is related more to impairment
while at work as opposed to loss of time from work. Longitudinal
analyses from REVEAL will elucidate how symptoms, QoL, and
work productivity change with time and disease progression.

Limitations
Responses to PRO questionnaires were missing for some patients,
which might introduce bias into the results.
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 Previous studies in which the MPN-SAF TSS was used to assess









symptom burden in patients with PV have been limited to international patients. In these previous evaluations, the symptoms
with the highest severity included fatigue, pruritus, and concentration problems.
When the MPN-SAF TSS was used to assess symptom burden in
US patients with PV enrolled in REVEAL, the symptoms with
the highest severity included fatigue, early satiety, and inactivity.
In this analysis, the symptom burden associated with PV appears
to have a negative effect on the QoL, daily activities, and work
productivity of some patients.
Although the primary management goal is to control blood
counts to decrease the risk of a ﬁrst or recurrent thrombotic
event, it is also important to regularly evaluate patients for
symptom burden, which might result in signiﬁcant morbidity in
these patients.
The MPN-SAF TSS form offers a concise, valid, and accurate
assessment of symptom burden that can be used in the clinic for
all patients with MPNs, including patients with PV.
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